J&J dumps $915M development deal with Hanmi as another Big Pharma abandons disaster-prone Korean drugmaker
Another one of Hanmi’s Big Pharma R&D alliances has ended up on the rocks.
Today it’s J&J’s turn to walk away from the South Korean pharma company, writing off a $105 million upfront and everything else it has spent trying to advance a new drug for diabetes and obesity since inking the deal close to 4 years ago.
Basic subscription required
Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.